# UHS SOTP VALUATION - THE CONCLUSION

**Prepared by:** Ascendra Capital
**Date:** October 29, 2025
**Target:** Universal Health Services (NYSE: UHS)

---

## ğŸ¯ THE BOTTOM LINE

**UHS is worth $449/share. It trades at $208. That's a 115% discount.**

**With Ascendra's operational improvements: $516/share (147% upside)**

---

## ğŸ’° WHAT'S IT WORTH? FOUR-PART BREAKDOWN

We valued UHS by **separating operations from real estate** for each business segment:

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚                    SOTP VALUATION BREAKDOWN                     â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                                 â”‚
â”‚  PART 1: Behavioral Health Operations                          â”‚
â”‚  â€¢ 324 facilities, 24,121 beds                                  â”‚
â”‚  â€¢ $1.8B EBITDA (22.7% margin - exceptional!)                  â”‚
â”‚  â€¢ Worth: 9.5x multiple = $17.3B (52% of value)                â”‚
â”‚                                                                 â”‚
â”‚  PART 2: Behavioral Health Real Estate                         â”‚
â”‚  â€¢ $3.9B in owned real estate (303 facilities)                 â”‚
â”‚  â€¢ 6.5% cap rate = $3.9B (12% of value)                        â”‚
â”‚                                                                 â”‚
â”‚  PART 3: Acute Care Operations                                 â”‚
â”‚  â€¢ 28 hospitals, 6,436 beds                                     â”‚
â”‚  â€¢ $1.4B EBITDA (13.5% margin - industry average)              â”‚
â”‚  â€¢ Worth: 7.0x multiple = $9.7B (29% of value)                 â”‚
â”‚                                                                 â”‚
â”‚  PART 4: Acute Care Real Estate                                â”‚
â”‚  â€¢ $2.7B in owned real estate (23 hospitals)                   â”‚
â”‚  â€¢ 6.5% cap rate = $2.7B (8% of value)                         â”‚
â”‚                                                                 â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•   â”‚
â”‚  TOTAL ENTERPRISE VALUE:           $33.5 Billion               â”‚
â”‚  Less: Net Debt                    ($4.4 Billion)              â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•   â”‚
â”‚  EQUITY VALUE:                     $29.2 Billion               â”‚
â”‚  Shares Outstanding:               65.0 Million                â”‚
â”‚  â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•â•   â”‚
â”‚  VALUE PER SHARE:                  $448.89                     â”‚
â”‚                                                                 â”‚
â”‚  Current Market Price:             $208.39                     â”‚
â”‚  Implied Upside:                   +115.4%                     â”‚
â”‚                                                                 â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## ğŸ¤” WHY IS IT SO CHEAP?

**The market makes 3 critical mistakes:**

### 1. Treating UHS as a Single Business

```
âŒ MARKET'S VIEW:
"UHS = healthcare company, apply 6.4x EBITDA"
= $17.9B enterprise value

âœ… REALITY:
"UHS = 4 different businesses with different values"
Behavioral OpCo:   9.5x (premium quality)
Behavioral RE:     6.5% cap (scarce assets)
Acute OpCo:        7.0x (industry standard)
Acute RE:          6.5% cap (hospital RE)
= $33.5B enterprise value

DIFFERENCE: 87% UNDERVALUATION
```

### 2. Not Seeing the Hidden Real Estate

- UHS **owns** 93.5% of its facilities (329 of 352)
- $6.6B in real estate on balance sheet at **book value**
- Market values this at zero (treats it as part of operations)
- **Reality:** Healthcare RE worth $6.6-7.8B at fair value (6-7% cap rates)

### 3. Ignoring Behavioral Quality

- Behavioral has **22.7% EBITDA margin** (best-in-class)
- Acute care has **13.5% EBITDA margin** (industry average)
- Market applies **same 6.4x multiple to both!**
- Should be: 9.5x for behavioral, 7.0x for acute

---

## ğŸ’¡ THE KEY INSIGHT: SOTP METHODOLOGY

**Why separate operations from real estate?**

When you **own** a facility, your reported EBITDA doesn't include rent expense.
This makes the EBITDA look "better" but actually **includes** the value of real estate.

**Example:**

```
FACILITY A (LEASED):
Revenue:              $100M
Operating Costs:      $85M
Rent Paid:            $10M
EBITDA:               $5M
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
OpCo Value: $5M Ã— 9x = $45M
PropCo Value: $10M / 6.5% = $154M
TOTAL: $199M

FACILITY B (OWNED):
Revenue:              $100M
Operating Costs:      $85M
Rent Paid:            $0 (owns it!)
EBITDA:               $15M â† Includes RE value!
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
If we value at 9x: $15M Ã— 9x = $135M â† WRONG! Undervalues RE

CORRECT APPROACH (SOTP):
Add back imputed rent:
Pro-Forma EBITDA:     $15M + $10M = $25M
OpCo Value: $25M Ã— 9x = $225M
PropCo Value: $10M / 6.5% = $154M
TOTAL: $379M â† CORRECT!
```

**This is why SOTP unlocks hidden value!**

---

## ğŸ“ˆ THREE SCENARIOS (BEAR / BASE / BULL)

| Scenario | Assumptions | Value/Share | Upside | Probability |
|----------|-------------|-------------|--------|-------------|
| **BEAR** | Behavioral 8x, Acute 6x, 7.5% cap | **$372** | **+78.6%** | 30% |
| **BASE** | Behavioral 9.5x, Acute 7x, 6.5% cap | **$449** | **+115.4%** | 50% |
| **BULL** | Behavioral 11x, Acute 8x, 5.5% cap | **$531** | **+154.6%** | 20% |

**Weighted Average Fair Value: $443/share**

**Even in the WORST CASE (bear), there's 79% upside!**

---

## ğŸš€ ASCENDRA VALUE CREATION: +$67/SHARE

### **Post-Acquisition Synergies: $433M Annual Run-Rate**

| Synergy Category | Annual Savings | Logic |
|------------------|----------------|-------|
| **Corporate Overhead** | $135M | Eliminate UHS C-suite, finance, legal, HR, IT (consolidate into Ascendra) |
| **Procurement** | $144M | Medical supplies, pharmaceuticals at Ascendra rates (combined $30B+ purchasing power) |
| **IT Systems** | $55M | Consolidate EHR, data centers, help desk, software licenses |
| **Facility Optimization** | $40M | Close/divest 3-5 underperforming acute hospitals |
| **Other Efficiencies** | $59M | Labor optimization, RCM improvements, shared services |
| **TOTAL** | **$433M** | **15.6% EBITDA uplift** |

**Value Creation:**
- $433M Ã— 10x multiple = **$4.3B**
- Per share: **$67**

**Combined Fair Value:**
- Base SOTP: $449
- + Synergies: $67
- **= $516/share**
- **vs. $208 current = 147% total upside**

---

## ğŸ’µ WHAT'S THE OPPORTUNITY?

### **For Ascendra (Acquirer):**

**Offer:** $333-375/share (60-80% premium)

| Metric | At $333 | At $375 | Why Smart |
|--------|---------|---------|-----------|
| Premium to Market | 60% | 80% | Well above typical 30-40% |
| Premium to Fair Value | **-26%** | **-16%** | **Still buying BELOW intrinsic value** |
| Post-Synergy Value | $516 | $516 | 55-90% IRR over 3 years |
| Miller Family Gets | $2.3B | $2.6B | Enough to overcome emotional attachment |

**Why This Works:**

```
Ascendra pays:              $355/share (midpoint)
Fair value:                 $449/share
Post-synergy value:         $516/share
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Value Creation:             $161/share (45% return)
Plus RE sale gains:         $5/share
â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€
Total Gain:                 $166/share (47% return)

3-Year IRR: 28-32% â† Exceptional
```

**Downside Protection:**
- Even if synergies **completely fail**, buying at $355 vs $449 = 26% margin of safety
- Even in **bear case** ($372), minimal downside risk
- Strong FCF ($1.4B/year) supports debt paydown

---

## ğŸ² KEY RISKS (AND WHY THEY'RE MANAGEABLE)

### **Risk 1: Miller Family Says No**
- **Probability:** 40%
- **Why It's OK:** Alan Miller is 87, needs succession planning. Premium is substantial ($2.3-2.6B to family). We can wait and try again.

### **Risk 2: Synergies Don't Materialize**
- **Probability:** 30%
- **Why It's OK:** Our $433M is conservative (industry benchmarks suggest $500M+). Even with ZERO synergies, buying at $355 vs $449 fair value = 26% upside.

### **Risk 3: Recession/Multiple Compression**
- **Probability:** 30%
- **Why It's OK:** Healthcare is defensive. Even in bear case (8x/6x multiples), worth $372 = still profitable at $355.

### **Risk 4: Integration Challenges**
- **Probability:** 60%
- **Why It's OK:** Budget 20% buffer on time/cost. Hire Big 4 integration team. Retain UHS operators (only eliminate corporate).

---

## ğŸ¦ CAPITAL STRUCTURE: CLEAN & MANAGEABLE

**Net Debt: $4.4B (1.58x EBITDA) - Investment Grade Quality**

### **Debt Breakdown:**

| Instrument | Amount | Rate | Maturity | Key Risk |
|------------|--------|------|----------|----------|
| Revolver | $130M drawn (90% available!) | 6.7% | 2029 | Massive liquidity cushion |
| Term Loan A | $1,190M | 6.7% | 2029 | $1.07B balloon in 2029 |
| Senior Notes 1.65% | $700M | 1.65% | **2026** | âš ï¸ Must refi in 18 months at ~5.5% |
| Senior Notes (other) | $2,300M | 2.65-5.05% | 2029-2034 | Well-laddered maturities |

**Key Strengths:**
- âœ… 1.58x Net Debt/EBITDA (well below 4.0x covenant)
- âœ… 14.9x EBITDA/Interest coverage (very strong)
- âœ… $1.4B annual free cash flow (12x debt service coverage)
- âœ… $1.2B available liquidity (90% of revolver unused)

**Key Risk:**
- âš ï¸ 2029 refinancing cliff: $1.6B due (term loan + notes)
- Mitigation: 4 years away, can prepay with FCF, strong credit for refi

**Ascendra Implications:**
- Clean balance sheet, easy to finance acquisition
- Can add $6.7B more debt at 4.0x covenant (massive capacity)
- Post-synergies, leverage drops to 1.1x (excellent)

---

## ğŸ¯ INVESTMENT RECOMMENDATION

### **FOR ASCENDRA:**

âœ… **PURSUE ACQUISITION AT $333-375/SHARE**

**Why:**
1. **Deep Value:** Buying at 26% discount to fair value, even before synergies
2. **Synergy Value Creation:** $433M annual savings = $67/share = 45% additional return
3. **Downside Protected:** Even in bear case, minimal risk. Strong FCF, investment grade credit.
4. **Strategic Fit:** Adds scale in behavioral health, creates national platform
5. **Executable:** Family control is feature not bug - single decision-maker to negotiate with
6. **Exceptional Returns:** 28-32% IRR over 3 years

**What Could Go Wrong:**
- Miller family rejects â†’ wait and try again (or walk away)
- Synergies fail â†’ still bought below fair value, margin of safety
- Recession â†’ healthcare is defensive, bear case still profitable

**Bottom Line:**
This is a **once-in-a-decade opportunity** to acquire the highest-quality behavioral health platform in America at a significant discount, with massive synergy potential and limited downside.

---

## ğŸ“Š THE DATA TO SUPPORT THIS

**All analysis backed by:**
- âœ… 21 CSV data files (extracted from UHS 10-K 2024)
- âœ… 4-part SOTP model with sensitivity analysis
- âœ… Complete capital structure analysis (every debt instrument)
- âœ… $433M synergy model (bottom-up, by category)
- âœ… Pro-forma financials (3-year with synergies)
- âœ… Acquisition premium analysis (20-80% scenarios)

**See detailed documents:**
1. `EXECUTIVE_SUMMARY_HILL_VALLEY_UHS_ACQUISITION.md` - Quick summary
2. `HILL_VALLEY_UHS_DETAILED_VALUATION_BOOK.md` - Full analysis (100+ pages)
3. `data/graphs/*.csv` - All 21 data tables

---

## ğŸ¬ NEXT STEPS

1. âœ… **Review this valuation** (you're here!)
2. â³ **Investment Committee approval** (present this analysis)
3. â³ **Engage M&A advisor** (Evercore, Centerview for confidential approach)
4. â³ **Approach Miller family** (friendly, private negotiation)
5. â³ **Due diligence** (60-90 days)
6. â³ **Definitive agreement** (negotiate terms)
7. â³ **Regulatory approval** (9-12 months)
8. â³ **Close & integrate** (realize synergies over 24-36 months)

---

**Prepared by:** Ascendra Capital Investment Team
**Date:** October 29, 2025
**Classification:** CONFIDENTIAL

**Questions? See the full valuation book or 21 data tables for details.**
